DBVT

Dbv Technologies S.a.

A French biopharmaceutical company that develops Viaskin, a skin-patch treatment for food allergies, with its lead product targeting peanut allergy. Founded in 2003 as a spin-off from France's national medical research institute INSERM and based near Paris, the company builds on the idea that allergy immunotherapy can be delivered through the skin instead of needles. Its name comes from the initials of its two physician founders, who pioneered the patch approach.

American Depositary Shares (each representing ordinary shares), listed on Nasdaq Global Select Market